1. Home
  2. HURA vs AVD Comparison

HURA vs AVD Comparison

Compare HURA & AVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HURA
  • AVD
  • Stock Information
  • Founded
  • HURA 2009
  • AVD 1969
  • Country
  • HURA United States
  • AVD United States
  • Employees
  • HURA N/A
  • AVD N/A
  • Industry
  • HURA
  • AVD Agricultural Chemicals
  • Sector
  • HURA
  • AVD Industrials
  • Exchange
  • HURA Nasdaq
  • AVD Nasdaq
  • Market Cap
  • HURA 103.3M
  • AVD 104.4M
  • IPO Year
  • HURA N/A
  • AVD N/A
  • Fundamental
  • Price
  • HURA $2.33
  • AVD $3.79
  • Analyst Decision
  • HURA Strong Buy
  • AVD Strong Buy
  • Analyst Count
  • HURA 2
  • AVD 1
  • Target Price
  • HURA $11.50
  • AVD $12.00
  • AVG Volume (30 Days)
  • HURA 475.4K
  • AVD 234.7K
  • Earning Date
  • HURA 08-15-2025
  • AVD 08-07-2025
  • Dividend Yield
  • HURA N/A
  • AVD N/A
  • EPS Growth
  • HURA N/A
  • AVD N/A
  • EPS
  • HURA N/A
  • AVD N/A
  • Revenue
  • HURA N/A
  • AVD $527,962,999.00
  • Revenue This Year
  • HURA N/A
  • AVD N/A
  • Revenue Next Year
  • HURA $69.15
  • AVD $3.54
  • P/E Ratio
  • HURA N/A
  • AVD N/A
  • Revenue Growth
  • HURA N/A
  • AVD N/A
  • 52 Week Low
  • HURA $1.80
  • AVD $3.28
  • 52 Week High
  • HURA $10.49
  • AVD $9.84
  • Technical
  • Relative Strength Index (RSI)
  • HURA N/A
  • AVD 46.37
  • Support Level
  • HURA N/A
  • AVD $3.90
  • Resistance Level
  • HURA N/A
  • AVD $4.25
  • Average True Range (ATR)
  • HURA 0.00
  • AVD 0.24
  • MACD
  • HURA 0.00
  • AVD 0.03
  • Stochastic Oscillator
  • HURA 0.00
  • AVD 60.70

About HURA TuHURA Biosciences Inc. Common Stock

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

About AVD American Vanguard Corporation ($0.10 Par Value)

American Vanguard Corp is a United States-based diversified specialty and agricultural products company. It manufactures and formulates chemicals for crops, turf and ornamental plants, and human and animal health protection. These chemicals include insecticides, fungicides, herbicides, molluscicides, growth regulators, and soil fumigants, which are marketed in liquid, powder, and granular forms.

Share on Social Networks: